CLARITY: Assessment of Venetoclax (ABT-199) in combination with Ibrutinib in relapsed/refractory Chronic Lymphocytic Leukaemia

Trial Overview and Summary

The aim of the CLARITY Study is to investigate the effectiveness and safety of ibrutinib used in combination with venetoclax in patients with CLL who are relapsed/refractory.  The trial may also give us information about how using both of the drugs together affects the rate of growth, and the lifespan, of leukaemia cells.

Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible

Chief Investigator:

Professor Peter Hillmen 


 University of Birmingham


 TAP Bloodwise

Disease Site:

 Chronic Lymphocytic Leukaemia

Trial Type:

 Clinical Trial of an Investigational Medicinial Product



UKCRN Study ID: (if applicable)


Open to new sites?


Recruitment start date:


Anticipated Recruitment end date


CRCTU Trial Management Team:


Trial E-mail Address:

Trial Protocol

Please Note:

Clinical trial protocols are complex technical documents which should only be used for the treatment of subjects taking part in the trial. Patients who are interested in taking part in the trial are advised to talk to their health care professional or refer to CancerHelp website.

Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference.

Trial documents [opens a new window]

More Information